HomeAI · summaries
Storia in 2 fonti
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Zydus Wellness enters harvest phase in FY27 as ₹7,800-crore acquisition bet faces execution test
Zydus Wellness enters FY27 aiming for ₹5,700 crore revenue, focusing on growth post-₹7,800 crore acquisitions amid execution challenges.
- ·
Zydus Lifesciences Q4 profit rises 8.7% to ₹1,272 crore; announces ₹1,100 crore buyback
Zydus Lifesciences Limited reported an 8.7% year-on-year increase in consolidated net profit that stood at ₹1,272 crore for the quarter ended March 2026, impacted by a one-time…
